FindTrial
Sign In

A study to investigate the efficacy of pomegranate in lowering lipid levels in hypertensive patients.

Punica Granatum and Antiatherosclerotic effect

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/04/003597
Enrollment
30
Registered
2013-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dyslipidemia and hypertensive

Interventions

Intervention1: Pomegranate Extract: Name of the drug â?? Generic: Punica Granatum
Brand: Pomella Name of active constituents â??Ellagic Acid Type of formulations â?? Fruit extract Drug dose - 400 mg twice a day (BD),orally for a total duration of 7 months and 15 days inclusive of c

Sponsors

Vir Chandra Singh Garhwali govtInstitute of Medical science and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a .Age group: between 30-60years(yrs). b. Gender:Of either gender. c. Those patients attending the OPD or admitted in the Medicine OPD and ward of HNB base hospital;Srikot. d. Patients on hypolipidemic and hypertensive medication. e .Patients whose general condition is fair.

Exclusion criteria

Exclusion criteria: a. Age restriction: 60 yrs b. No other concomitant medication except for antihypertensives. c. Patients with general condition not fair. d. Inability to come for regular follow up if attending OPD.

Design outcomes

Primary

MeasureTime frame
To see the antiatherosclerotic effect of PomegranateTimepoint: Eight months—

Secondary

MeasureTime frame
To see adverse effect if anyTimepoint: Eight months—

Countries

India

Contacts

Public ContactDrHeenopama Thakur

Vir Chandra Singh Garhwali Govt. Institute of Medical Science and Research institute

vijaythawani@rediffmail.com7579039260

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026